Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
نویسندگان
چکیده
Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a key driver of macular oedema in RVO. In 2010, ranibizumab was approved in the USA for the treatment of macular oedema in RVO and, in 2011, ranibizumab was approved in the European Union for the treatment of visual impairment caused by macular oedema secondary to RVO in branch and central RVO. Ranibizumab provides an additional therapeutic option for this complex disease: an option that was not fully considered during the preparation of current international guidelines. An expert panel was convened to critically evaluate the evidence for treatment with ranibizumab in patients with visual impairment caused by macular oedema secondary to RVO and to develop treatment recommendations, with the aim of assisting physicians to optimise patient treatment.
منابع مشابه
Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion.
AIM To evaluate the association between the size of peripheral retinal non-perfusion and the number of intravitreal ranibizumab injections in patients with treatment-naive branch retinal vein occlusion (BRVO) and macular edema. METHODS A total of 53 patients with treatment-naive BRVO and macular edema were included. Each patient underwent a full ophthalmologic examination including optical co...
متن کاملRanibizumab in Circulatory Disorder of Retinal Vein: an Evidence-based Approach
The discovery of anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) agents is a clear breakthrough with exciting potential in medical management of retinal diseases.Ranibizumab is a humanized, affinitymatured VEGF antibody fragment that binds to and neutralizes all isoforms of VEGF, which has first received FDA approval for the treatment of macular edema due to both c...
متن کاملAnti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion
PURPOSE To evaluate the association between the size of peripheral retinal nonperfusion and the number of intravitreal ranibizumab injections in patients with treatment-naïve central retinal vein occlusion (CRVO). METHODS Fifty-four patients with treatment-naïve CRVO and macular edema were included. Each patient underwent a full ophthalmologic examination including optical coherence tomograph...
متن کاملEfficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion
OBJECTIVES To evaluate the effects and safety of intravitreal ranibizumab on visual acuity and anatomic results in the treatment of macular edema due to retinal vein occlusion (RVO). METHODS Forty Six eyes of 45 patients who were administered intravitreal ranibizumab because of macular edema due to Retinal Vein Occlusion (RVO) were included in this retrospective clinical study. During monthly...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 99 شماره
صفحات -
تاریخ انتشار 2015